EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next batter up! Targeting cancers with KRAS-G12D mutations

Mara N Zeissig, Lauren M Ashwood, Olga Kondrashova, Kate D Sutherland

Trends in Cancer · 2023-11 · 9 (11) · 955-967

DOI: 10.1016/j.trecan.2023.07.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-11. Verfasst von Mara N Zeissig und 3 weiteren Autor:innen. Beteiligte Einrichtung: ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, 3052, Australia; De…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Adenocarcinoma. Die Arbeit wurde bisher 138-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victorian Cancer Agency, National Health and Medical Research Council, Cure Cancer Australia Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS is the most frequently mutated oncogene in cancer. Activating mutations in codon 12, especially G12D, have the highest prevalence across a range of carcinomas and adenocarcinomas. With inhibitors to KRAS-G12D now entering clinical trials, understanding the biology of KRAS-G12D cancers, and identifying biomarkers that predict therapeutic response is crucial. In this Review, we discuss the genomics and biology of KRAS-G12D adenocarcinomas, including histological features, transcriptional landscape, the immune microenvironment, and how these factors influence response to therapy. Moreover, we explore potential therapeutic strategies using novel G12D inhibitors, leveraging knowledge gained from clinical trials using G12C inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)AdenocarcinomaHumansMutationTumor Microenvironment

Stichwörter der Autor:innen

KRASKRAS G12DMRTX1133adenocarcinomatumor suppressor

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, 3…
  • QIMR Berghofer Medical Research Institute, Herston, 4006, Australia; The University of Queensland, Brisbane, 4072, Australia.

Förderung

  • Victorian Cancer Agency
  • National Health and Medical Research Council
  • Cure Cancer Australia Foundation

Zitieren

APA

Zeissig, M. N., Ashwood, L. M., Kondrashova, O., & Sutherland, K. D. (2023). Next batter up! Targeting cancers with KRAS-G12D mutations. Trends in Cancer, 9(11), 955-967. https://doi.org/10.1016/j.trecan.2023.07.010

Vancouver

Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends in Cancer. 2023;9(11):955-967. doi:10.1016/j.trecan.2023.07.010

BibTeX
@article{Zeissig2023,
  author = {Zeissig, Mara N and Ashwood, Lauren M and Kondrashova, Olga and Sutherland, Kate D},
  title = {Next batter up! Targeting cancers with KRAS-G12D mutations},
  journal = {Trends in Cancer},
  year = {2023},
  volume = {9},
  number = {11},
  pages = {955--967},
  doi = {10.1016/j.trecan.2023.07.010}
}
Kostenlos starten →